Harbin Pharmaceutical Group Co. Ltd Financials

Market Capitalization CN¥9.67 Billion as of July 1, 2025

Valuations Metrics as of Jul. 5, 2025

Trailing PE	14.77
Forward PE	12.80
Price to Sales TTM	CN¥0.60
Price to Book MRQ	CN¥1.74
Enterprise to Revenue	0.53
Enterprise to EBITDA	7.95

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	4.10%
Operating Margin	6.43%
Return on Assets TTM	3.86%
Return on Equity TTM	12.06%

Income Statement

Revenue TTM	CN¥16,208,119,808
Revenue per Share TTM	CN¥6.36
Quarterly Revenue Growth	0.80%
Gross Profit TTM	CN¥4,456,769,536
EBITDA	CN¥1,023,238,584
Net Income to Common TTM	CN¥665,034,560
Diluted EPS TTM	CN¥0.26
Quarterly Earnings Growth YoY	20.50%

Balance Sheet

Total Cash MRQ	CN¥2,802,289,664
Total Cash per Share MRQ	CN¥1.11
Total Debt MRQ	CN¥
Total Debt to Equity MRQ	21.48
Current Ratio MRQ	1.42
Book Value per Share MRQ	CN¥2.21

Cash Flow

Operating Cash Flow TTM	CN¥598,724,608
Levered Free Cash Flow TTM	CN¥572,499,264

600664 Stock Info as of Jul. 5, 2025

Stock Statistics

Shares Outstanding	2,518,509,876
Float Shares	1,292,650,379
Avg 10 Volume	39,719,993
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	51.14%
% Held by Institutions	3.90%

Stock Price Summary

Beta	0.27
Fifty Two Week Low	CN¥2.54
Fifty Two Week High	CN¥4.97
Fifty Two Week Change	32.03%
Day 50 MA	CN¥3.74
Day 200 MA	CN¥3.76

Dividends and Splits

Forward Annual Dividend Rate	CN¥
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	CN¥0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2018-05-04
Last Split Factor
Last Split Date	2016-04-06